Next Article in Journal
MicroRNA Processing and Human Cancer
Next Article in Special Issue
MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment
Previous Article in Journal
Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients
Previous Article in Special Issue
MicroRNAs as Signaling Mediators and Biomarkers of Drug- and Chemical-Induced Liver Injury
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(8), 1631-1650;

MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas

Department of Surgery, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia
Institute of Pathology, Medizinische Hochschule Hannover, Hannover D30625, Germany
Authors to whom correspondence should be addressed.
Academic Editor: Rajagopal N. Aravalli
Received: 29 June 2015 / Revised: 28 July 2015 / Accepted: 6 August 2015 / Published: 18 August 2015
(This article belongs to the Special Issue MicroRNAs: Novel Biomarkers for Liver Diseases)
Full-Text   |   PDF [269 KB, uploaded 18 August 2015]   |  


The discovery of small non-coding RNAs known as microRNAs has refined our view of the complexity of gene expression regulation. In hepatocellular carcinoma (HCC), the fifth most frequent cancer and the third leading cause of cancer death worldwide, dysregulation of microRNAs has been implicated in all aspects of hepatocarcinogenesis. In addition, alterations of microRNA expression have also been reported in non-cancerous liver diseases including chronic hepatitis and liver cirrhosis. MicroRNAs have been proposed as clinically useful diagnostic biomarkers to differentiate HCC from different liver pathologies and healthy controls. Unique patterns of microRNA expression have also been implicated as biomarkers for prognosis as well as to predict and monitor therapeutic responses in HCC. Since dysregulation has been detected in various specimens including primary liver cancer tissues, serum, plasma, and urine, microRNAs represent novel non-invasive markers for HCC screening and predicting therapeutic responses. However, despite a significant number of studies, a consensus on which microRNA panels, sample types, and methodologies for microRNA expression analysis have to be used has not yet been established. This review focuses on potential values, benefits, and limitations of microRNAs as new clinical markers for diagnosis, prognosis, prediction, and therapeutic monitoring in HCC. View Full-Text
Keywords: microRNA; hepatocellular carcinoma; biomarker; diagnosis; prognosis; therapeutic monitoring microRNA; hepatocellular carcinoma; biomarker; diagnosis; prognosis; therapeutic monitoring

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Anwar, S.L.; Lehmann, U. MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. J. Clin. Med. 2015, 4, 1631-1650.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top